Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Towia Libermann

Beth Israel Deaconess Medical Center, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

BiomaRx

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

NA

Listed Research Project
Identification of Plasma- and Exosome-Based Protein Biomarkers for Early Detection of Pancreatic Cancer Using SOMAscan Technology

PROJECT NARRATIVE Pancreatic cancer is anticipated to affect more than 53,000 Americans this year and is the third leading cause of cancer death in the United States, with the high death rate largely due to the lack of tools to detect and diagnose pre-symptomatic pancreatic cancer at earlier, more treatable stages. To help bridge this crucial gap, we will apply a new cutting edge, highly sensitive technology to identify protein biomarkers in blood and exosome samples that discriminate patients with early stages of pancreatic cancer from patients with chronic pancreatitis or late onset diabetes, patient groups at increased risk of pancreatic cancer and for whom the diagnosis of pancreatic cancer can be challenging, and healthy controls. Discovery of an accurate plasma and exosome diagnostic and predictive biomarkers for early stage pancreatic cancer will improve screening, monitoring, and treatment strategies and may enhance knowledge of biological pathways in order to prevent, diagnose, monitor, and treat this deadly disease. !

Filed on November 19, 2018.

Tell us what you know about Towia Libermann's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page